Aptadir Ce-49 / Aptadir Therapeutics - LARVOL DELTA

Launch of Aptadir Therapeutics With a Novel Class of RNA Inhibitors (Businesswire) - "Aptadir Therapeutics...announces its launch and the appointment of Giovanni Amabile as Executive Chairman and acting CEO...Aptadir was founded by Dr Annalisa Di Ruscio and Dr Vittorio De Franciscis, both leaders in the field of RNA biology and DNA methylation, alongside Prof. Daniel Tenen, an expert in MDS and leukaemia, and Prof. Marcin Kortylewski, an expert in oligonucleotide immunotherapeutics...The first programme, Aptadir Ce-49 is being developed in MDS and the aim is to enter the clinic by the end of 2025....Aptadir has received $1.6m in pre-seed funding from the EXTEND initiative to optimize its lead asset, Aptadir Ce-49. The Company is the first to receive funding from EXTEND, which is the Italian National Technology Transfer Hub wholly dedicated to the biopharmaceutical sector for the development of new therapeutic approaches."

Financing • New molecule • New trial • Hematological Malignancies • Myelodysplastic Syndrome • Oncology